Danaher Corporation (DHR)
| Market Cap | 161.37B |
| Revenue (ttm) | 24.27B |
| Net Income (ttm) | 3.50B |
| Shares Out | 706.35M |
| EPS (ttm) | 4.87 |
| PE Ratio | 46.94 |
| Forward PE | 28.23 |
| Dividend | $1.28 (0.56%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | 4,135,264 |
| Open | 229.57 |
| Previous Close | 230.77 |
| Day's Range | 227.47 - 230.95 |
| 52-Week Range | 171.00 - 258.23 |
| Beta | 0.93 |
| Analysts | Strong Buy |
| Price Target | 245.27 (+7.36%) |
| Earnings Date | Oct 21, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for man... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $245.27, which is an increase of 7.36% from the latest price.
News
3 More Good Stocks to Invest In After Earnings
These cheap stocks from wide-moat companies look attractive today.
Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Danaher Corporation ( DHR) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Rainer Blair - President, CEO & Director Conference Call Participants Tycho P...
The Big 3: TMO, DHR, VLO
As A.I. stocks take a beating on Wednesday's trading session, Dan Deming offers his thoughts and example options trades in healthcare and energy stocks. He explains his bullish theses behind Thermo Fi...
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon
A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.
Danaher to Present at Jefferies Global Healthcare Conference
WASHINGTON , Nov. 11, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare ...
Top 15 High-Growth Dividend Stocks For November 2025
The Top 15 High-Growth Dividend Stock list for November 2025 offers a 1.39% yield and 19.88% five-year dividend growth. Despite underperforming SPY and VIG in October, the watchlist targets a long-ter...
DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE...
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Co...
DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher ...
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to ...
These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings
Danaher Corporation (NYSE:DHR) reported better-than-expected third-quarter financial results on Tuesday.
Danaher: Regaining Growth Momentum
Danaher Corporation is regaining growth momentum, with strong Q3 results, positive 2026 guidance, and robust performance in its Biotechnology segment. DHR's management maintains conservative full-year...
Danaher Still A Hold: Good Q3 Results Alone Don't Make A Great Investment
Danaher Corporation reported solid Q3/25 results with 4.4% revenue growth and improved margins, yet valuation concerns persist. Despite management's optimism for high single-digit long-term growth, Da...
Here's Why Shares in Danaher Got Boosted Higher Today
Danaher's biotechnology growth prospects look assured. Guidance for 2026 is merely within the range of current market expectations.
Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President, CEO & Director Mat...
Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?
Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion and non-GAAP adjusted EPS of $1.89, significantly outpa...
Danaher beats quarterly estimates on strength in diagnostic tools and tech
Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3...
Danaher Sales and Profit Rise on Bioprocessing Momentum
Danaher recorded higher third-quarter sales and profit on the back of momentum in its bioprocessing business and better-than-expected sales in its respiratory market.
Danaher Reports Third Quarter 2025 Results
WASHINGTON , Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key Third Quarter 2025 Results Net earnings...
Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher ...
Danaher Stock: Monopoly Margins, Discounted Price
Danaher (NYSE:DHR) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
3 Top Healthcare Stocks to Buy in October
Healthcare stocks have lagged the broader stock market over the past year. Political tensions following the slaying of an insurance executive and policy uncertainty following the transition to the Tru...
4 Stocks That Aren't Too Hot to Buy Right Now
Evergy, Danaher, Quanta, and Kinetik are all set to deliver big, Citi analysts calculate.
Danaher: Balanced Portfolio With Upside Potential In 2026
Danaher is undervalued, with strong fundamentals, robust free cash flow, and a "Buy" rating targeting $210 (12.7% upside). DHR's bioprocessing segment drives growth, balancing Life Sciences weakness, ...
Danaher Schedules Third Quarter 2025 Earnings Conference Call
WASHINGTON , Sept. 23, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2025 on Tuesday, October 21, 202...